Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Amgen

The move gives the agency time to weigh a settlement that would allow the deal to close with conditions.

FTC Pauses Challenge to Amgen's $27.8 Billion Deal for Horizon Therapeutics

The FTC pulled back one of its efforts to block Amgen's Horizon buyout, according to a document released Friday that sent HZNP stock flying.

Horizon Therapeutics Jumps On A New FTC Development In The Amgen Takeover Battle

Horizon Therapeutics reports better-than-expected Q2 results, easing concerns about the Amgen acquisition failing to close due to Horizon's business underperformance. Net sales of Tepezza have been a key issue, but positive label changes and phase 4 results are expected to drive demand, and the major headwinds are now behind. Krystexxa and Uplizna continue to show strong growth, adding value to the acquisition.

Improved Outlook For Horizon Therapeutics And Amgen

Celsius Holdings

NVIDIA

The U.S. stock market has been rattled by a range of events and yet sits within 7% of an all-time high. Along the way, however, many publicly traded companies have gone bankrupt or been delisted.

Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.07 per share a year ago.

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

Amgen beat second-quarter expectations Thursday and raised its outlook for the year, helping push Amgen stock higher in late action.

Amgen Beats Expectations, Raises Outlook With Horizon Takeover In The Wings

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

AbbVie

DiCE Molecules Holding LLC

Eli Lilly

Pfizer

Seagen

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) injection with methotrexate, a commonly used immunomodulator, in ACR Open Rheumatology [https://doi.org/10.1002/acr2.11578]. “Publication of these 12-month data reinforces key findings shown at Month 6, including the durability of urate-lowering response, reduced infusion reactions and reduced immu.

Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology

Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.

Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced presentations of new results from the randomized, double-blind, placebo-controlled Phase 2 trial showing dazodalibep, an investigational treatment for Sjögren's syndrome, may improve some of the most prominent effects of this chronic, systemic autoimmune condition characterized by inflammation of exocrine glands. These are the first presentations of the Phase 2 trial results and are part of expert dialogue this wee.

Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout. Presentations are part of expert discussions at the EULAR European Congress of Rheumatology, May 31 - June 3, 2023, in Milan. Data presented from Horizon's MIRROR randomized control.

New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology

Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter as the re-rating starts to look interesting with fundamental valuations starting to provide support. Despite continued uncertainty on the Horizon deal, related to regulatory approval, I am slowly warming up to Amgen, with or without Horizon.

Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'

There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong oncology portfolio and is planning to acquire Seagen, a company with an entire focus on cancer treatments.

FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?

The judge who will decide if Amgen can go forward with its $27.8 billion purchase of Horizon Therapeutics on Tuesday said he was considering an evidentiary hearing on the matter in September.

US judge hearing fight over Amgen deal for Horizon eyes September trial

The new timeline is earlier than what Amgen, Horizon Therapeutics and Wall Street analysts were initially expecting after the FTC sued to block the deal.

Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it

Shares of Horizon Therapeutics (HZNP) are fresh off their lowest level since November, after the Federal Trade Commission (FTC) yesterday said it will block the acquis

Buy The Dip On The FTC's Latest Victim

A U.S. district court has issued a temporary restraining order on Amgen Inc's $27.8 billion acquisition of Horizon Therapeutics following a submission for it by the two companies and the U.S. Federal Trade Commission, Amgen said on Wednesday.

U.S. court issues temporary restraining order on $27.8 bln Amgen-Horizon deal

The FTC wants to block Amgen's acquisition of Horizon even though the two companies' products don't overlap. The agency thinks that Amgen could try to bundle Horizon's products in a way that discourages competition.

FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?

Colgate-Palmolive

Chevron

Johnson & Johnson

Phillips 66

Paul Tudor Jones (Trades, Portfolio), founder and chief investment officer of Boston-based Tudor Investment Group, disclosed in a regulatory filing that his firm's top buys during the first quarter included new positions in Phillips 66 ( PSX , Financial) and Johnson & Johnson ( JNJ , Financial). The firm also boosted its holdings of Horizon Therapeutics ( HZNP , Financial), Chevron Corp. ( CVX , Financial) and Colgate-Palmolive Co. ( CL , Financial).

Top 5 Buys of Paul Tudor Jones' Firm in the 1st Quarter

The Dow and S&P 500 moved lower Tuesday morning. Sea Limited shares fell as the company's video game segment failed to meet expectations.

Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday

The FTC is attempting to stop the sale out of fears it will give the company too much power over rare disease treatments.

News for Horizon Pharma Stock (HZNP)